Melissa S. Cline
Research Subjects
Research Interests
Melissa S. Cline has a total of 392 co-authors. Here are the top co-authors by number of shared publications:
- Alex Handler Wagner
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH
5 shared publications - James Casaletto
Blue Marble Space Institute of Science, Space Biosciences Division, NASA Ames Research Center, Moffett Field, CA 94035, USA
5 shared publications - Lawrence Babb
Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
5 shared publications - Robert R. Freimuth
Mayo Clinic, Rochester, MN
5 shared publications - Malachi Griffith
Washington University
4 shared publications - Michael Baudis
University of Zürich
4 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by JMIR Publications Inc. in JMIRx Bio
- Vol. 4 (1) , e73041
Machine Learning Ensemble Investigates Age in the Transcriptomic Response to Spaceflight in Murine Mammary Tissue: Observational Study
Background: Spaceflight presents unique environmental stressors, such as microgravity and radiation, that significantly affect biological systems at the molecular, cellular, and organismal levels. Astronauts face an increased risk of developing cancer due to exposure to ionizing radiation and other spaceflight-related factors. Age plays a crucial role in the body’s response to the cellular stresses that lead to cancer, with younger organisms generally exhibiting more efficient response mechanisms than older ones. The vast majority of research investigating breast cancer risk from spaceflight uses cell lines exposed to simulated radiation and microgravity, but cell lines cannot capture the combinatorial response expressed across tissues, organs, and systems to real radiation and microgravity in space. Objective: The primary objective of this in silico observational study is to characterize the molecular response to spaceflight of in vivo murine mammary tissue. We use an ensemble of linear binary classifiers to identify the molecular biomarkers enriched in this response using mice flown on the International Space Station. The secondary objective is to determine if age plays a role in this response. Methods: The National Aeronautics and Space Administration (NASA) Open Science Data Repository has curated transcriptomic data obtained from 10 BALB/cAnNTac female mice flown on the International Space Station and 33 control mice kept on earth (OSD-511). In this observational study focused on two age groups (old/young), we used an ensemble of 4 machine learning binary classifiers with linear decision boundaries (logistic regression, support vector machine, stochastic gradient descent, and single-layer perceptron) to analyze gene expression profiles to predict age (old vs young) and condition (spaceflight vs ground control). Using the genes our ensemble identified as most predictive, we performed pathway enrichment analysis to investigate the molecular pathways involved in spaceflight-related health risks, particularly in the context of breast cancer. Results: The pathway enrichment analyses revealed age-differentiated responses to spaceflight (false discovery rate–adjusted q values<.05). Among the 10 mice flown in space, younger mice exhibited significantly enriched pathways related to lipid metabolism and inflammatory stress signaling. All space-flown mice demonstrated evidence of adaptation in retinoid metabolism and peroxisome proliferator-activated receptor signaling in response to microgravity and radiation relative to their 33 ground control counterparts. Conclusions: Spaceflight-induced breast cancer risk manifests through distinct age-specific mechanisms: younger individuals face risk through maladaptive metabolic hyperactivity and oxidative cycling, while older individuals are vulnerable due to impaired stress responses and accumulated metabolic dysfunction. Both age groups ultimately face elevated carcinogenic potential through different but converging pathways. These findings highlight the critical role of age in modulating the response to spaceflight-induced stress and suggest that these molecular pathways may contribute to differential outcomes in tissue homeostasis, metabolic disorders, and breast cancer susceptibility.
- 14 January 2026
- Published by JMIR Publications Inc. in JMIRx Bio
- Vol. 4 (1) , e73041
Open AccessMachine Learning Ensemble Investigates Age in the Transcriptomic Response to Spaceflight in Murine Mammary Tissue: Observational Study
Background: Spaceflight presents unique environmental stressors, such as microgravity and radiation, that significantly affect biological systems at the molecular, cellular, and organismal levels. Astronauts face an increased risk of developing cancer due to exposure to ionizing radiation and other spaceflight-related factors. Age plays a crucial role in the body’s response to the cellular stresses that lead to cancer, with younger organisms generally exhibiting more efficient response mechanisms than older ones. The vast majority of research investigating breast cancer risk from spaceflight uses cell lines exposed to simulated radiation and microgravity, but cell lines cannot capture the combinatorial response expressed across tissues, organs, and systems to real radiation and microgravity in space. Objective: The primary objective of this in silico observational study is to characterize the molecular response to spaceflight of in vivo murine mammary tissue. We use an ensemble of linear binary classifiers to identify the molecular biomarkers enriched in this response using mice flown on the International Space Station. The secondary objective is to determine if age plays a role in this response. Methods: The National Aeronautics and Space Administration (NASA) Open Science Data Repository has curated transcriptomic data obtained from 10 BALB/cAnNTac female mice flown on the International Space Station and 33 control mice kept on earth (OSD-511). In this observational study focused on two age groups (old/young), we used an ensemble of 4 machine learning binary classifiers with linear decision boundaries (logistic regression, support vector machine, stochastic gradient descent, and single-layer perceptron) to analyze gene expression profiles to predict age (old vs young) and condition (spaceflight vs ground control). Using the genes our ensemble identified as most predictive, we performed pathway enrichment analysis to investigate the molecular pathways involved in spaceflight-related health risks, particularly in the context of breast cancer. Results: The pathway enrichment analyses revealed age-differentiated responses to spaceflight (false discovery rate–adjusted q values<.05). Among the 10 mice flown in space, younger mice exhibited significantly enriched pathways related to lipid metabolism and inflammatory stress signaling. All space-flown mice demonstrated evidence of adaptation in retinoid metabolism and peroxisome proliferator-activated receptor signaling in response to microgravity and radiation relative to their 33 ground control counterparts. Conclusions: Spaceflight-induced breast cancer risk manifests through distinct age-specific mechanisms: younger individuals face risk through maladaptive metabolic hyperactivity and oxidative cycling, while older individuals are vulnerable due to impaired stress responses and accumulated metabolic dysfunction. Both age groups ultimately face elevated carcinogenic potential through different but converging pathways. These findings highlight the critical role of age in modulating the response to spaceflight-induced stress and suggest that these molecular pathways may contribute to differential outcomes in tissue homeostasis, metabolic disorders, and breast cancer susceptibility.
- Open Access
- 14 January 2026
- Published by JMIR Publications Inc. in JMIRx Bio
- Vol. 4 (1) , e88583
Authors’ Response to Peer Reviews of “Machine Learning Ensemble Investigates Age in the Transcriptomic Response to Spaceflight in Murine Mammary Tissue: Observational Study”
This is the author(s)' response to peer review reports related to "Machine Learning Ensemble Investigates Age in the Transcriptomic Response to Spaceflight in Murine Mammary Tissue: An Observational Study"
- 14 January 2026
- Published by JMIR Publications Inc. in JMIRx Bio
- Vol. 4 (1) , e88583
Open AccessAuthors’ Response to Peer Reviews of “Machine Learning Ensemble Investigates Age in the Transcriptomic Response to Spaceflight in Murine Mammary Tissue: Observational Study”
This is the author(s)' response to peer review reports related to "Machine Learning Ensemble Investigates Age in the Transcriptomic Response to Spaceflight in Murine Mammary Tissue: An Observational Study"
- Open Access
When Two plus Four Does Not Equal Six: Combining Computational and Functional Evidence to Classify BRCA1 Key Domain Missense Substitutions.
Classification of genetic variants remains an obstacle to realizing the full potential of clinical genetic sequencing. Because of their ability to interrogate large numbers of variants, multiplexed assays of variant effect (MAVEs) and computational tools are viewed as a critical part of the solution to variant classification uncertainty. However, the (joint) performance of these assays and tools on novel variants has not been established. Transformation of the qualitative classification guidelines developed by the American College of Medical Genetics and Genomics (ACMG) into a quantitative Bayesian point system enables empirical validation of strength of evidence assigned to evidence criteria. Here, we derived a maximum likelihood estimate (MLE) model that converts frequentist odds ratios calculated from case-control data to proportions pathogenic and applied this model to functional assays, alone and in combination with, computational tools across several domains of BRCA1. Furthermore, we defined exceptionally conserved ancestral residues (ECARs) and interrogated the performance of assays and tools at these residues in BRCA1. We found that missense substitutions in BRCA1 that fall at ECARs are disproportionately likely to be pathogenic with effect sizes similar to that of protein truncating variants. In contrast, for substitutions falling at non-ECAR positions, concordant predictions of pathogenicity from functional assay and computational tool fail to meet the additive assumptions of strength in ACMG guidelines. Thus, collectively, we conclude that strengths of evidence assigned by expert opinion in the ACMG guidelines are not universally applicable and require empirical validation.
Open AccessWhen Two plus Four Does Not Equal Six: Combining Computational and Functional Evidence to Classify BRCA1 Key Domain Missense Substitutions.
Classification of genetic variants remains an obstacle to realizing the full potential of clinical genetic sequencing. Because of their ability to interrogate large numbers of variants, multiplexed assays of variant effect (MAVEs) and computational tools are viewed as a critical part of the solution to variant classification uncertainty. However, the (joint) performance of these assays and tools on novel variants has not been established. Transformation of the qualitative classification guidelines developed by the American College of Medical Genetics and Genomics (ACMG) into a quantitative Bayesian point system enables empirical validation of strength of evidence assigned to evidence criteria. Here, we derived a maximum likelihood estimate (MLE) model that converts frequentist odds ratios calculated from case-control data to proportions pathogenic and applied this model to functional assays, alone and in combination with, computational tools across several domains of BRCA1. Furthermore, we defined exceptionally conserved ancestral residues (ECARs) and interrogated the performance of assays and tools at these residues in BRCA1. We found that missense substitutions in BRCA1 that fall at ECARs are disproportionately likely to be pathogenic with effect sizes similar to that of protein truncating variants. In contrast, for substitutions falling at non-ECAR positions, concordant predictions of pathogenicity from functional assay and computational tool fail to meet the additive assumptions of strength in ACMG guidelines. Thus, collectively, we conclude that strengths of evidence assigned by expert opinion in the ACMG guidelines are not universally applicable and require empirical validation.
- Open Access
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS, and previous findings indicate that case-control likelihood ratios (LRs) outperform odds ratios for variant classification. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyzed germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 303,925 unaffected controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observed 11,227 BRCA1 and BRCA2 variants, with 6,921 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control LR evidence was highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.4% specificity for BRCA1 and 92.2% sensitivity and 86.6% specificity for BRCA2 . This approach provides case-control evidence for 785 unclassified variants, that can serve as a valuable element for clinical classification.
Open AccessAnalysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS, and previous findings indicate that case-control likelihood ratios (LRs) outperform odds ratios for variant classification. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyzed germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 303,925 unaffected controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observed 11,227 BRCA1 and BRCA2 variants, with 6,921 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control LR evidence was highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.4% specificity for BRCA1 and 92.2% sensitivity and 86.6% specificity for BRCA2 . This approach provides case-control evidence for 785 unclassified variants, that can serve as a valuable element for clinical classification.
- Open Access
- 25 August 2023
- Published by Annual Reviews in Annual Review of Genomics and Human Genetics
- Vol. 24 (1) , 347-368
Federated Analysis for Privacy-Preserving Data Sharing: A Technical and Legal Primer
Continued advances in precision medicine rely on the widespread sharing of data that relate human genetic variation to disease. However, data sharing is severely limited by legal, regulatory, and ethical restrictions that safeguard patient privacy. Federated analysis addresses this problem by transferring the code to the data—providing the technical and legal capability to analyze the data within their secure home environment rather than transferring the data to another institution for analysis. This allows researchers to gain new insights from data that cannot be moved, while respecting patient privacy and the data stewards’ legal obligations. Because federated analysis is a technical solution to the legal challenges inherent in data sharing, the technology and policy implications must be evaluated together. Here, we summarize the technical approaches to federated analysis and provide a legal analysis of their policy implications.
- 25 August 2023
- Published by Annual Reviews in Annual Review of Genomics and Human Genetics
- Vol. 24 (1) , 347-368
Open AccessFederated Analysis for Privacy-Preserving Data Sharing: A Technical and Legal Primer
Continued advances in precision medicine rely on the widespread sharing of data that relate human genetic variation to disease. However, data sharing is severely limited by legal, regulatory, and ethical restrictions that safeguard patient privacy. Federated analysis addresses this problem by transferring the code to the data—providing the technical and legal capability to analyze the data within their secure home environment rather than transferring the data to another institution for analysis. This allows researchers to gain new insights from data that cannot be moved, while respecting patient privacy and the data stewards’ legal obligations. Because federated analysis is a technical solution to the legal challenges inherent in data sharing, the technology and policy implications must be evaluated together. Here, we summarize the technical approaches to federated analysis and provide a legal analysis of their policy implications.
- Open Access
Development and application of a computable genotype model in the GA4GH Variation Representation Specification
As the diversity of genomic variation data increases with our growing understanding of the role of variation in health and disease, it is critical to develop standards for precise inter-system exchange of these data for research and clinical applications. The Global Alliance for Genomics and Health (GA4GH) Variation Representation Specification (VRS) meets this need through a technical terminology and information model for disambiguating and concisely representing variation concepts. Here we discuss the recent Genotype model in VRS, which may be used to represent the allelic composition of a genetic locus. We demonstrate the use of the Genotype model and the constituent Haplotype model for the precise and interoperable representation of pharmacogenomic diplotypes, HGVS variants, and VCF records using VRS and discuss how this can be leveraged to enable interoperable exchange and search operations between assayed variation and genomic knowledgebases.
Open AccessDevelopment and application of a computable genotype model in the GA4GH Variation Representation Specification
As the diversity of genomic variation data increases with our growing understanding of the role of variation in health and disease, it is critical to develop standards for precise inter-system exchange of these data for research and clinical applications. The Global Alliance for Genomics and Health (GA4GH) Variation Representation Specification (VRS) meets this need through a technical terminology and information model for disambiguating and concisely representing variation concepts. Here we discuss the recent Genotype model in VRS, which may be used to represent the allelic composition of a genetic locus. We demonstrate the use of the Genotype model and the constituent Haplotype model for the precise and interoperable representation of pharmacogenomic diplotypes, HGVS variants, and VCF records using VRS and discuss how this can be leveraged to enable interoperable exchange and search operations between assayed variation and genomic knowledgebases.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1177
Abstract 1177: Introduction of the GA4GH Variation Representation Specification (VRS) and supporting tools for discovery and exchange of clinical genomic and cytogenomic knowledge in cancers
Precision oncology is the practice of interpreting the clinical significance of observed molecular changes in patient neoplasms, potentially impacting medical decision making and care. This process is labor-intensive and (among other challenges) involves accurately translating between variation representation conventions from one resource to the next. For example, differences in representations of Copy Number Variation (CNV) from genomic regions, cytogenomic bands, or gene features create challenges in knowledge matching due to lack of standards covering all of these modalities of observed variation.The Global Alliance for Genomics and Health (GA4GH; ga4gh.org) is an international collaborative of genomic data sharing initiatives (Driver Projects) developing genomic data sharing standards within a human rights framework. GA4GH recently published the Variation Representation Specification (VRS; pronounced “verse”), a standard for the computational representation of biomolecular variation. VRS is a terminology, schema, and associated conventions for creating uniquely identifiable and federatable representations of molecular variation. VRS has formal data classes well-suited to differentiating between variation on a single molecule (e.g. tandem duplications) from variation measured at a systemic level (e.g. genome-wide copy number variation). In addition to molecular sequence variation, VRS also supports variation on cytogenetic coordinate systems and genes, making it well-suited to representing variation associated with cancer biomarkers.We demonstrate the use of VRS to model reported gene-associated CNVs from the AACR Project GENIE cohort, to aid in the computational discovery of evidence from clinico-genomic knowledgebases with genomic or cytogenomic CNV representations. We highlight the use case of knowledge matching to the Atlas of Genetics and Cytogenetics in Oncology and Haematology (“the Atlas”; atlasgeneticsoncology.org), a cytogenetics resource historically driven by user website navigation. Using VRS search tools we developed for the Variant Interpretation for Cancer Consortium (VICC; cancervariants.org) GA4GH Driver Project, we found that 64% of GENIE samples with reported CNVs matched clinically relevant knowledge in the Atlas. This work was enabled by programmatic search tools leveraging standard VRS object structures, demonstrating how VRS enables collection of real-world evidence across more resources without manual interpretation or custom normalization methods. We conclude with a survey of open-source tools supporting this analysis as well as search of other clinico-genomic knowledgebases with VRS, including CIViC (civicdb.org), BRCA Exchange (brcaexchange.org), and the Molecular Oncology Almanac (moalmanac.org). Citation Format: Matthew Cannon, Kori Kuzma, James Stevenson, Jiachen Liu, Colin O'Sullivan, Bimal P. Chaudhari, Matthew Brush, Robert R. Freimuth, Tristan Nelson, Michael Baudis, Obi L. Griffith, Malachi Griffith, Lawrence Babb, Melissa S. Cline, Xuelu Liu, Brian Walsh, Alex H. Wagner. Introduction of the GA4GH Variation Representation Specification (VRS) and supporting tools for discovery and exchange of clinical genomic and cytogenomic knowledge in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1177.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1177
Open AccessAbstract 1177: Introduction of the GA4GH Variation Representation Specification (VRS) and supporting tools for discovery and exchange of clinical genomic and cytogenomic knowledge in cancers
Precision oncology is the practice of interpreting the clinical significance of observed molecular changes in patient neoplasms, potentially impacting medical decision making and care. This process is labor-intensive and (among other challenges) involves accurately translating between variation representation conventions from one resource to the next. For example, differences in representations of Copy Number Variation (CNV) from genomic regions, cytogenomic bands, or gene features create challenges in knowledge matching due to lack of standards covering all of these modalities of observed variation.The Global Alliance for Genomics and Health (GA4GH; ga4gh.org) is an international collaborative of genomic data sharing initiatives (Driver Projects) developing genomic data sharing standards within a human rights framework. GA4GH recently published the Variation Representation Specification (VRS; pronounced “verse”), a standard for the computational representation of biomolecular variation. VRS is a terminology, schema, and associated conventions for creating uniquely identifiable and federatable representations of molecular variation. VRS has formal data classes well-suited to differentiating between variation on a single molecule (e.g. tandem duplications) from variation measured at a systemic level (e.g. genome-wide copy number variation). In addition to molecular sequence variation, VRS also supports variation on cytogenetic coordinate systems and genes, making it well-suited to representing variation associated with cancer biomarkers.We demonstrate the use of VRS to model reported gene-associated CNVs from the AACR Project GENIE cohort, to aid in the computational discovery of evidence from clinico-genomic knowledgebases with genomic or cytogenomic CNV representations. We highlight the use case of knowledge matching to the Atlas of Genetics and Cytogenetics in Oncology and Haematology (“the Atlas”; atlasgeneticsoncology.org), a cytogenetics resource historically driven by user website navigation. Using VRS search tools we developed for the Variant Interpretation for Cancer Consortium (VICC; cancervariants.org) GA4GH Driver Project, we found that 64% of GENIE samples with reported CNVs matched clinically relevant knowledge in the Atlas. This work was enabled by programmatic search tools leveraging standard VRS object structures, demonstrating how VRS enables collection of real-world evidence across more resources without manual interpretation or custom normalization methods. We conclude with a survey of open-source tools supporting this analysis as well as search of other clinico-genomic knowledgebases with VRS, including CIViC (civicdb.org), BRCA Exchange (brcaexchange.org), and the Molecular Oncology Almanac (moalmanac.org). Citation Format: Matthew Cannon, Kori Kuzma, James Stevenson, Jiachen Liu, Colin O'Sullivan, Bimal P. Chaudhari, Matthew Brush, Robert R. Freimuth, Tristan Nelson, Michael Baudis, Obi L. Griffith, Malachi Griffith, Lawrence Babb, Melissa S. Cline, Xuelu Liu, Brian Walsh, Alex H. Wagner. Introduction of the GA4GH Variation Representation Specification (VRS) and supporting tools for discovery and exchange of clinical genomic and cytogenomic knowledge in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1177.
- Open Access
- 9 March 2022
- Published by Elsevier in Cell Genomics
- Vol. 2 (3)
Federated analysis of BRCA1 and BRCA2 variation in a Japanese cohort
- 9 March 2022
- Published by Elsevier in Cell Genomics
- Vol. 2 (3)
Open AccessFederated analysis of BRCA1 and BRCA2 variation in a Japanese cohort
- Top Cited PapersOpen Access
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
GA4GH: International policies and standards for data sharing across genomic research and healthcare
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
Top Cited PapersOpen AccessGA4GH: International policies and standards for data sharing across genomic research and healthcare
- Open Access
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
The GA4GH Variation Representation Specification: A computational framework for variation representation and federated identification
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
Open AccessThe GA4GH Variation Representation Specification: A computational framework for variation representation and federated identification